Overview

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well fludarabine and cyclophosphamide followed by peripheral stem cell transplant works in treating patients with leukemia or lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer and Leukemia Group B
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate